ANDA 75432, held by Ani Pharms. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75432 (Doxazosin Mesylate), held by Ani Pharms, was first approved by FDA on Oct 18, 2000, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Jan 31, 2002 | Supplement 3Manufacturing | Approved | None posted |
| Jan 31, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Oct 18, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters